Triple

T10214547
Position Surface form Disambiguated ID Type / Status
Subject Janssen Biotech E242407 entity
Predicate hasBlockbusterDrug P7501 FINISHED
Object Remicade E49851 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Remicade | Statement: [Janssen Biotech, hasBlockbusterDrug, Remicade]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Remicade
Context triple: [Janssen Biotech, hasBlockbusterDrug, Remicade]
  • A. Remicade chosen
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • B. Humira
    Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
  • C. Stelara
    Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
  • D. Kevzara
    Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
  • E. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: hasBlockbusterDrug
Context triple: [Janssen Biotech, hasBlockbusterDrug, Remicade]
  • A. hasDrug
    Indicates that an entity possesses, is treated with, or is associated with a particular drug.
  • B. hasNotableDrug chosen
    Indicates that an entity is associated with a drug that is considered notable or significant in some recognized context.
  • C. isFirstDrugApprovedFor
    Indicates that a drug is the earliest or original medication approved for treating a particular condition, disease, or indication.
  • D. hasBiosimilar
    Indicates that one biological product is a biosimilar counterpart to another reference biological product.
  • E. hasOrphanDrugDesignation
    Indicates that a drug or therapeutic product has been granted orphan drug designation by a regulatory authority, recognizing it as intended for the treatment of a rare disease or condition.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d381ae26c48190985abd0e25ee5d04 completed April 6, 2026, 9:49 a.m.
NER Named-entity recognition batch_69d3aa273bdc8190bc4cf67a7923cebc completed April 6, 2026, 12:42 p.m.
NED1 Entity disambiguation (via context triple) batch_69d87e27c2dc8190a5b3173fbcb01114 completed April 10, 2026, 4:35 a.m.
PD Predicate disambiguation batch_69d39559e5ac8190b88eca75956b7e6a completed April 6, 2026, 11:13 a.m.
Created at: April 6, 2026, 11:04 a.m.